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Abstract 
 
Background 
 
In recent years the association between sexual dysfunction (SD) and obesity in the general 
population has drawn major attention. Although sexual dysfunction is common in psychosis, 
its relationship with weight gain and obesity remains unclear. 
Aims 
 
To investigate the association between sexual dysfunction and obesity in a cohort of patients 
with first episode psychosis. 
Method 
 
Sexual function was assessed in a cohort of patients with first episode psychosis using the 
Sexual Function Questionnaire (SFQ). Anthropometric measures, including weight, BMI, 
waist, waist-hip ratio were investigated. Additionally, leptin and testosterone were 
investigated in male patients. 
Results 
 
A total of 1 1 6  p a t i e n t s  ( 61 males and 55 females) were included. Of these 59% of 
males and 67.3% of females showed sexual dysfunction (SD) according to the SFQ. In 
males, higher SFQ scores were significantly correlated with higher BMI (Std. β=.36, p= 
.01), higher leptin levels (Std. β=. 34, p=. 02), higher waist-hip ratio (Std. β=. 32, p= .04) 
and lower testosterone levels (Std. β=-.44, p= .002). In contrast, in females, SFQ scores 
were not associated with any of these factors. 
Conclusions 
 
While sexual dysfunction is present in both female and male patients with their first episode 
of psychosis, only in males is sexual dysfunction associated with increased BMI and waist- 
hip ratio. The association between SD, BMI, low levels of testosterone and high levels of 
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leptin suggest that policies that lead to healthier diets and more active lifestyles can be 
beneficial at least, to male patients. 
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1. Introduction 
 
 
The association between sexual dysfunction (SD) and heavier weight and obesity in 
the general population has recently drawn considerable attention1-3. More specifically, 
erectile dysfunction in healthy males has been observed in association with obesity and other 
abnormal metabolic parameters1, as well as with high levels of leptin and low levels of 
testosterone2, 4. 
It is of interest that some of these factors, such as abnormal testosterone 5 and increased leptin 
levels6 have also been reported as altered in patients with first episode psychosis, who also 
exhibit high rates of SD7. For example, prevalence rates of up to 37 - 65% of SD have been 
reported in patients with FEP 7, 8. Furthermore, patients with FEP often present weight gain 
and metabolic abnormalities, mainly attributed to the use of antipsychotics9-12. 
 
A relationship between being overweight and central obesity on one side, and higher levels of 
leptin 13 and lower levels of testosterone on the other has been proposed to explain the 
presence of hypogonadism and sexual dysfunction in the general population. According to 
this, the excessive circulating levels of leptin seen in the overweight might disrupt the 
steroidogenic function of the Leydig cells, with a subsequent reduction in hCG-driven 
testosterone production and testosterone deficiency as a final result4, 14, 15. This testosterone 
deficiency has then been found to be associated with both hypogonadism and SD. 2, 3, 16-18 
However, so far, few studies have investigated the potential causes of SD in FEP 
patients 8, 19. To our knowledge, none has explored the relationship between SD, weight, 
testosterone, leptin and central obesity in patients with FEP. More specifically, no previous 
study has investigated whether hyperleptinaemia and testosterone deficiency may explain, at 
least in part, the sexual dysfunction often seen in patients with first episode psychosis; and 
how weight gain is associated with increased levels of leptin  and  decreased  values  of  
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testosterone  and  ultimately  with  sexual  dysfunction. Studying these factors in patients at 
their first psychotic episode has several advantages: individuals have been exposed to 
medication for a relatively short period of time, and are less likely to suffer from residual 
and negative symptoms. 
In a sample of patients at their first psychotic episode we investigated the following 
hypotheses: 1) that the presence of SD would be associated with being overweight, as 
indicated by higher weight and BMI, larger waist, waist-hip ratio; 2) that in male patients 
sexual dysfunction would be associated with overweight, lower testosterone and higher leptin 
plasma levels. 
 
2. Methods 
 
 
2.1 Design 
 
 
 
 
This was a cross-sectional study of patients with first episode psychosis, conducted in the 
South London and Maudsley (SLAM) and Oxleas and Sussex Partnership NHS Trusts. The 
study was approved by the Ethics Committees of these Trusts (ref. # 1275/SUPA/2009). 
 
 
 
2.2 Participants 
 
 
 
 
Patients presenting for the first time to psychiatric services with a functional psychotic illness 
(ICD10: F=20-29 excluding coding F1x.0 for acute intoxication), psychotic symptoms lasting 
for at least 7 days and with an age between 18–65 years were approached from August 2008 to 
July 2011. Researchers screened for potential participants at the beginning of each week 
through a variety of means to ensure the maximum level of recruitment and minimise selection 
6  
bias. They took a list of all new admissions and screened clinical notes to assess for eligibility. 
Researchers attended weekly team meetings where the cases were discussed with doctors, 
nurses and healthcare assistants. Once a patient was deemed suitable, researchers would 
approach the potential participant and invited to participate in the study. The specifics of the 
project would be fully described and patients would be given the information and consent 
sheets. If patients were willing to participate and able to give informed consent, they were 
requested to read through the information sheet, invited to ask any questions and confirm that 
they fully understood the study and eventually sign the consent form.  
Exclusion criteria were: presence of an organic psychosis, a moderate or severe learning 
disability (as defined by ICD-10 F=70-73, WHO, 1992), pregnancy, history of a medical or 
physiological cause of gonadal or sexual dysfunction (including hypothyroidism or other 
endocrine or metabolic disorder, vascular disorders and neurological disorders) 7, 22, 23, lack of 
English fluency (requiring a translator), history of contact with health services (GP or mental 
health services) for psychosis beyond the previous 6 months. 
 
A total of 286 patients consented to the study. Of the 286 potential patients at baseline, 27 were 
subsequently excluded for not satisfying the criteria for a first episode of psychosis or needing 
a translator, leaving a sample of 259 eligible participants. A further 40 patients dropped out 
leaving a final sample of 219 patients available for baseline assessments. At baseline, 
information on sexual dysfunction were available on 116 subjects. 
 
 
 
 
2.3 Study Procedure 
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Sociodemographic data (age, gender, self-reported ethnicity, level of education attainment, and 
employment status) on subjects were collected using the Medical Research Council Social 
Scale 20. Medication histories were completed using information directly from patients and 
double checked with both inpatients and outpatients’ electronic records. Total days of exposure 
to antipsychotic medication was intended to be a lifetime exposure. This was calculated by 
converting the antipsychotic daily dose into chlorpromazine equivalent and multiplied for the 
total number of days the subject was exposed to antipsychotic- this was taken as a cumulative 
dose of antipsychotics. The date when the first prescription was issued was as start date and the 
date of completion of assessments and point of entry to our study was used as end date. 
Antipsychotic doses were converted into chlorpromazine equivalents using established 
criteria21. Daily and cumulative dose of antipsychotics was used as an indicator of impact of 
antipsychotics on sexual function and to determine whether there was a relationship between 
dose and outcome. 
 
 
 
Sexual dysfunction was evaluated with the short Sexual Function Questionnaire (SFQ) 22. 
The SFQ is a self-report structured instrument that has been previously validated in patients 
with psychotic disorders 22, 23. Higher scores indicate greater impairment, and a total SFQ 
score equal or higher than 8 is considered a cut off indicating the presence of sexual 
dysfunction. The Positive and Negative Syndrome Scale (PANSS) 24 was used to evaluate 
psychotic and negative symptoms in patients with psychosis, as there is evidence of an 
association between sexual dysfunction and negative symptoms in patients with chronic 
psychosis 25, 26. Depressive symptoms were assessed with Calgary Depression Score (CDS 27) 
as previous studies have shown that low mood can impact sexual function in the general 
population 28-30. Researchers with extensive training rated PANSS and CDS. Inter-rater 
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variability for PANSS and CDS was 0.95 and 0.96 respectively. A detailed history of illicit 
drug use (cannabis, stimulants, and any other recreational drug) was taken using the Cannabis 
Experience Questionnaire modified version31. Anthropometric measures such as weight, 
waist, hip, waist-hip ratio, BMI were recorded on the day of assessment together with serum 
levels of prolactin, leptin and testosterone. 
 
 
 
 
 
2.4. Laboratory Procedures 
 
 
 
 
Patients were asked to fast and abstain from eating or drinking (except plain water) from 
midnight until 8 am of the day on which a blood sample was collected by an experienced 
phlebotomist. Samples were analyzed by the King’s Pathology Laboratory at King’s College 
Hospital, London.  
 
Testosterone was analysed using a radio-immuno-enzymatic procedure that uses testosterone labelled with 
acridinium ester and an anti-testosterone antibody bound to paramagnetic particles to produce a light emission 
reaction.  Intra-assay precision was calculated as Mean 3.31 (nmol/L) for Level 1 with CV of 6.2%.  Sensitivity 
was 0.5 nmol/L. Reagents were provided by Siemens Healthcare Diagnostics Ltd. 
 
Leptin was measured with a quantitative sandwich enzyme immunoassay technique. A monoclonal antibody 
specific for leptin was pre-coated onto a microplate. Standards and samples were pipetted in duplicate for a 
minimum of 30 microL into the wells and any leptin present was bound by the immobilised antibody. After 
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washing away any unbound substances, an enzyme-linked monoclonal antibody specific for leptin was added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution was added to 
the wells - colour develops in proportion to the amount of leptin bound in the initial step. The colour development 
was stopped and the intensity of the colour was measured. Intra-assay precision was calculated as mean 64.5 
(pg/mL) with 2.14 SD and CV 3.3 %.  The analytical sensitivity of leptin was 7.8 pg/mL.  Elisa kit was supplied 
by R & D Systems Europe Ltd.   
 
Prolactin was measured using Bayer Advia Centaur assay- which is a two-site sandwich immunoassay that uses 
direct chemiluminometric technology. Light intensity is measured and converted to light units. This has a direct 
proportional relationship with the prolactin concentration. Intra-assay precision was Mean: 69.9 (IU/L) with 2.6 
% CV .  Sensitivity was  6.4 IU/L.  Reagents were supplied by Siemens Healthcare Diagnostics Ltd.   
 
Anthropometric measures- namely weight, height, waist and hip circumference- were taken 
with subjects wearing light clothing and no shoes, and after having emptied their pockets. 
Waist circumference was measured by taking belly button as a point of reference, the tape 
measure was put on it and the patient was asked to wrap it around them. The measurement of 
the hip circumference was taken at the point yielding the maximum circumference over the 
buttocks, with the tap held in a horizontal plane touching the skin but not indenting the soft 
tissues.  
 
2.5 Statistical analyses 
 
 
 
 
In view of different female and male sexual physiology, analyses were conducted separately 
for each gender group. In both groups all variables were tested for normal distribution with 
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Kolmogorov-Smirnov test.  The variables that did not follow a normal distribution were 
transformed using log-transformation or square root. In males those variables were: SFQ 
total score, prolactin and leptin serum levels and cumulative dose of antipsychotics. In 
females: prolactin serum levels, weight and hip and cumulative dose of antipsychotics. 
Exploratory partial correlations between SFQ and anthropometric and blood measures were 
conducted with daily and cumulative dose of antipsychotics, prolactin serum levels, 
PANSS, CDS as potential confounders. Only a p-value equal or less than 0.01 was accepted 
as significant to control for multiple testing. 
Subsequently, regression analysis was used to calculate the association between SFQ and 
those outcome measures that reached statistical significance (less than 5%) in the exploratory 
analyses. Standardized beta (Std. β) is presented to allow comparison between variables and 
to assess the strength of the effect (Std. β of 0.14, 0.39 and 0.59 correspond to Cohen’s 
definition of small, medium and large effect sizes respectively) 32. From the preliminary 
analysis only prolactin and PANSS total score were found to have an effect on outcome 
measures when used as covariates. CDS was therefore excluded from further analysis. 
Pearson correlation was also conducted between main outcome measures and covariates to 
identify those highly correlated and avoid problems of multicollinearity with the regression 
analysis. Waist-hip ratio, BMI, testosterone and leptin were also highly correlated; therefore, 
a separate linear multiple regression was performed for each, with SFQ as dependent variable 
and prolactin, cumulative dose of antipsychotics and PANSS total score as covariates. 
 
3. Results 
 
 
 
 
A total of 116 subjects (61 males and 55 females) were included in the analyses. 
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Demographic characteristics and values for each outcome variable are presented in Table 1. 
Of the patients included, 60 were Caucasians, 43 were Black African/African-Caribbean and 
13 were of other ethnic background (7 of mixed ethnicity and 6 Asian). At the time of 
baseline assessments, a total of 102 subjects were taking antipsychotics (45 Olanzapine, 24 
Risperidone, 21 Aripiprazole, 7 Quetiapine, 2 Haloperidol, 1 Amisulpride, 1 Sulpiride and 1 
 
Trifluoperazine). Thirteen subjects were antipsychotic-naive and 1 patient had missing data. 
Among those prescribed with antipsychotics, the average duration of treatment with 
antipsychotics prior to assessment was 54 days (Std ± 55); the mean daily dose of 
antipsychotics, expressed as chlorpromazine equivalents, was 242.05 mg (Std. ± 178.01) 
while the mean cumulative dose of antipsychotic was 14690.03 mg (Std ± 17789.91). At the 
time of the baseline assessments, only 6 subjects were taking antidepressants (2 Sertraline, 3 
Fluoxetine and 1 Escitalopram), 1 person was taking a mood stabilizer (sodium valproate) 
and 3 people benzodiazepines (clonazepam).  Sixty-four subjects had been using cannabis 
before first contact with the services. 
The subjects taking antidepressants were excluded from further analyses for small sample 
size as well as in view of the pronounced effects of selective serotonin re-uptake inhibitors 
on sexual function 33. 
 
The prevalence of obesity in male and female participants did not differ significantly (16.4 
and 17.4 respectively, chi-square =0.019, df=1,p=0.891). Regarding obesity, we tested for 
mean differences in BMI with respect to medication. According to one way ANOVA there 
were no statistically significant differences (F(4.95)=0.104, p=0.981). With respect to 
sexual dysfunction, there were no statistically significant association to medication in 
males. For females, the association was significant (Fisher’s exact test: Chi=14.7273, 
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p=0.003). Specifically, among those who received olanzapine the percentage of those 
having sexual dysfunction was much higher than those who did not (48.6% versus 5.6%). 
This result however should be treated with caution as only 1 out of 19 women did not 
have sexual dysfunction (SFQ>=8). Additionally, among those who received aripiprazole, 
the percentage of those having sexual dysfunction was much lower than those who did not 
(10.8% versus 44.4%). No statistical differences were found for the rest of the 
antipsychotic medication. 
The diagnosis was later ascertained using OPCRIT criteria34 with following results: 
Schizophrenia 48.4%, Mania with psychosis 18.7%, Schizoaffective Disorder Depressive 
Type 5.5%, Schizoaffective Disorder Manic Type 4.4%, Depressive Episode Severe with 
psychotic features 8.8%, Moderate Depressive Episode 4.4%, Bipolar Affective Disorder  
1%, Unspecified Non Organic Psychosis 1%, Delusional Disorder 1%, No criteria met 
6.6%. 
 
 
 
 
 
 
3.1. Correlation between sexual function and metabolic measures 
 
 
 
 
A total of 59% males presented with SD, in comparison with 67.3% of women. Women 
showed higher dysfunction in reduction of sexual libido (N=30; 54.5%) and arousal (N=17; 
30.9%), while men showed greater difficulty in achieving orgasm (N= 39; 63.9%). 
 
 
 
 
3.1.1.Males 
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A partial correlation, with cumulative dose of antipsychotics, prolactin serum levels, and 
total score for PANSS as covariates showed that higher SFQ scores were significantly 
correlated with higher BMI (r=.39, p=.02)   and increased leptin levels (r=.38, p=.02), and 
lower levels of testosterone (r=-.50, p≤ .003). Correlations with weight, hip and waist as 
other outcome measures were not significant (p-values > 0.05). 
 
 
 
The measures, which reached statistical significance in this exploratory analysis, were entered 
in a linear multiple regression, with SFQ as dependent variable and PANSS, prolactin and 
cumulative dose of antipsychotics as covariates. Results showed that a larger waist-hip ratio 
(Std. β=. 32, p= .04; see Fig.1), higher BMI (Std. β= .36, p= .01; see Fig. 2) and increased 
serum leptin levels (Std. β= .34, p= .02) were significantly associated with higher scores of 
SFQ, with a marginal contribution to the model of prolactin serum levels (Std. β=. 29, 
p=.05). Lower levels of testosterone also significantly predicted higher SFQ scores (Sd. β=-
.44, p= .002; see Fig. 3). 
 
3.1.2 Females 
 
In   females, we   performed   a   partial   correlation   between   higher   SFQ   scores   and 
anthropometric measures, including cumulative dose of antipsychotics, prolactin and PANSS 
scores together with CDS values as covariates. This showed no significant association 
between SD and any of the variable (all p-values > 0.05 with weight: r= .01 p=.46; waist: 
r=.10 p=.30; hip: r=.15 p=.23; waist-hip ratio: r= - .03 p=.43; BMI: r=.06 p=.37). Therefore, 
no regression analysis was performed. 
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4.Discussion 
 
 
 
 
This is the first study to investigate the association between SD and ’an estimate of 
visceral fat’ in a cohort of patients with FEP. To our knowledge this is also the first 
study to report that waist-hip ratio and BMI are strong predictors of sexual dysfunction in 
male patients, and more importantly, to demonstrate an association between SD and 
testosterone and leptin levels in FEP. Our findings suggest that this effect is not simply 
mediated by antipsychotic exposure, since leptin and testosterone remained strong predictors 
of SD even when the exposure to antipsychotics was considered in the analysis. Our main 
finding is that SD is predicted by higher BMI and waist-hip ratio. While there are several 
reports2, 4, 18 indicating an association between visceral obesity and sexual dysfunction in the 
general population, there is none reporting such association in patients with psychosis 
Being overweight has been correlated with hypogonadism in the general population2. In fact, 
hypogonadism may contribute to the accumulation of excess fat and to the reduction of 
insulin-sensitive muscular mass with increase in insulin resistance, leading to the onset of 
metabolic disorders2. It is proposed that men with SD, and/or with visceral obesity should be 
screened for testosterone deficiency and treated for weight reduction35-37. This would result in 
potential benefit in leptin reduction and increase of testosterone levels. 
The second major finding of this study is that high levels of leptin and low levels of 
testosterone predict sexual dysfunction. This seems to be mediated by weight gain through 
leptin increase. Leptin is a cytokine released by adipocytes to regulate energy homeostasis 13. 
It is possible that the weight gain -subsequent to antipsychotics load- is what induces leptin 
increase. In turn, leptin metabolizes testosterone to estradiol via an aromatase, with subsequent 
reduction of testosterone levels 4. This facilitates the fatty acid uptake and triglyceride 
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storage. The overall result is an increase in fat stores, which further increases leptin 
production and subsequently increases aromatase activity. This drives the cycle even further, 
with higher levels of leptin and further reduction in testosterone concentration (for a review 
see 18). Isidori et al. 4 have clearly demonstrated that leptin concentrations are negatively 
correlated with total and free testosterone, and that leptin is a potent hormonal predictor of 
decreased androgen concentrations in obese men. They concluded that in obese men, high 
leptin concentrations inhibit the production of testosterone disrupting the steroidogenic 
function of Leydig cells. Therefore, low testosterone could be considered one of the many 
adverse consequences of being overweight and obesity 2. 
Weight gain in patients with FEP seems to be associated with the use of antipsychotics 9-12. 
In order to prevent or reduce the risk of SD, u se  o f  weight inducing antipsychotics 
should be limited, when possible; alternatively, patients should engage in a variety of 
interventions like wellness programs, CBT, nutritional education and diet, weight 
management and exercise to improve physical health or health perception 38- 44. 
A recent meta-analysis by Bonfioli et al. 44 has demonstrated that when compared to 
treatment as usual, lifestyle interventions including diet and physical activity reduce weight 
in patients with psychosis by −0.98 BMI points. Unfortunately, despite the introduction of 
guidelines for metabolic screening in schizophrenia, metabolic monitoring in routine clinical 
practice is still unusual 46. Another interesting finding of this study relates to the female 
sample. Although a higher percentage of women presented with sexual dysfunction than males 
(67.3% vs. 59%), no association between SD and obesity or any other outcome measures 
was found. This may suggest that sexual dysfunction in women is not driven by fat 
excess or fat distribution. Males and females differ in terms of how and where body fat is 
stored, and also in the type of hormones they secrete in proportion to their fat47. 
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Postmenopausal women seem to accumulate more fat in the intra-abdominal depot than do 
premenopausal women, and therefore are at greater risk of developing metabolic 
complications associated with obesity, similarly to men 47. Only 4 women in our study were 
postmenopausal and we did not study the testosterone and leptin cycle in this group since 
there is no evidence of such an association in the literature. Also, it is worth noting that the 
female sexual arousal response seems to be mediated, apart from testosterone, by several 
physiological modulators such as vasoactive intestinal polypeptide (VIP), nitric oxide (NO), 
and prostaglandin E (PGE) that regulate vaginal smooth muscle contractility48. Future 
investigations of female sexual dysfunction should aim to investigate these factors. 
Our results also indicate that prolactin marginally contributes to sexual dysfunction (Std. β=. 
29, p= .05). Although this finding is in line with some studies 26, 49, is in contrast with others 
7, 23. Antipsychotics such as risperidone, amisulpride, and paliperidone induce higher 
prolactin levels and seem associated with higher incidence of SD compared to antipsychotics 
that do not (quetiapine, aripiprazole, ziprasidone, and olanzapine)50. However, some 
studies do not find differences in SD among patients taking different antipsychotics 7, 8, 19, 
23, 51 - 53. In our sample, 39 males patients were taking prolactin-sparing  antipsychotics  and  
15  were  taking  prolactin-elevating antipsychotics,  while  6  were  drug  naive.  
Unfortunately, the number of patients taking prolactin-elevating antipsychotics was too 
small to allow a separate analysis to investigate the specific role of prolactin. These results 
should be therefore taken with caution. 
Some limitations need to be considered when interpreting our findings. For example, we did 
not include a healthy control group. However, it is of note that similar clinical findings and 
molecular pathways have been proposed in non-psychotic male subjects in which SD has been 
associated with visceral obesity and mediated by leptin and testosterone 2-4, 15, 18.  
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Furthermore we believe is crucial to attract attention towards a more holistic approach to 
mental health which includes also sexual health. This subject is often disregarded amongst 
mental health professionals. 54, 55We think that offering new evidence of  the pathophysiological 
mechanism that links fat tissues with testosterone metabolism3,4 also in patients with mental 
illness at greater risks of sexual dysfunction due to increased risks of weight gain because of 
antipsychotic treatment needs to alert psychiatrists to put greater effort in reducing weight gain 
and promoting wellbeing and healthy living. 39-46 
Also, we could not  examine  sub-domains  of sexual  function  owing to  power limitations,  
and  so further studies are needed to determine whether there are particular domains of sexual 
dysfunction that are associated with metabolic abnormalities. Furthermore, we could not 
explore in details the impact of substance use on sexual dysfunction because of our sample 
size. However, an exploratory analysis on cannabis smokers did not show any impact of 
cannabis on male sexual function (data not shown). Nevertheless, the interaction between 
substance use and SD should be further investigated in larger samples. 
In summary, impaired sexual function in male patients with first episode of psychosis is 
associated with visceral obesity, low testosterone and high leptin levels- independently of 
antipsychotic exposure. These preliminary results warrant an even more careful assessment 
of weight gain, fat distribution and sexual dysfunction in patients at the early stages of 
psychosis, since these conditions have a considerable impact on their quality of life and are 
probably a major factor in non-adherence to prescribed antipsychotic drugs53. They also 
suggest that an earlier implementation of prevention strategies that provide healthier diets 
and more active lifestyles is required55, 56. This type of intervention can help 
prevention of cardiovascular disease and promote higher fulfillment of such an important 
aspect of quality of life such as intimacy and sexuality. 
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Table 1. Demographic characteristics of sample at baseline and main outcome measures 
 Total 
(n = 116) 
Males 
(n = 61) 
Females 
(n = 55) 
Demographics    
Age, years: mean (SD) 29 (9)  28 (8)  30 (10) 
Ethnicity, n (%)    
 White 60 (51.7)  25 (41) 35 (63.6) 
 Black-African/African-Caribbean 43 (37.1) 29 (47.5) 14 (25.5) 
 Other 13 (11.2)  7  (11.5)  6  (10.9) 
Symptom scores; mean (SD)    
Sexual Function Questionnaire 10.2 (5.6) 9.6 (5.2)  10.9 (5.7) 
Calgary Depression Scale 5.3 (5.1) 4.5 (4.6)  6.3 (5.4) 
Positive and Negative Syndrome 
Scale 
56.0 (14.2) 55.6 (13.8)  56.6 (14.7) 
Anthropometrics; mean (SD)    
Body Mass Index  25.5 (5.6) 25.4 (5.0)  25.7 (6.2) 
Waist-hip ratio  0.85 (0.08) 0.87 (0.07)  0.83 (0.08) 
Weight (kg) 76.2 (18.7) 80.0 (16.4)  71.6 (20.4) 
Waist (cm) 88.7 (14.2) 89.9 (12.6)  87.2 (15.8) 
Hip (cm) 103.4 (13.3) 102.7 (9.0)  104.8 (16.9) 
Biochemistry; mean (SD)    
Prolactin (mIU/L) 700.3 (983.1) 432.2 (350.6)  1057.9 (1375.7) 
Leptin (ng/mL) - 6.9 (6.2) - 
Testosterone (nmol/L) - 20.0 (6.3) - 
Abbreviations: SD=Standard Deviation; Normal Values: Sexual Function Questionnaire ≤ 8; Calgary Depression Scale ≤ 5; Positive and 
Negative Syndrome Scale 30-210; Body Mass Index: 18-25; Waist-hip ratio: for Males ≤ .95; for Women ≤ .80; Waist: for Males ≤ 94 cm, for 
Women ≤ 80; Prolactin: 40-500 mIU/L; Leptin: for Males (2.21 – 11.15 ng/mL), for Females (3.88 – 77.27 ng/mL); Testosterone: for Males (10 -
30 nmol/L), for Females (0.5 - 2.6).
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Fig. 1. Association between SFQ and waist-hip ratio in male patients with FEP. Linear 
trend line and 95%confidence interval of simple linear regression is plotted in the data. 
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Fig. 2. Association between  SFQ and  BMI in male patients with FEP. Linear trend line 
and 95%confidence interval of simple linear regression is plotted in the data. 
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Fig. 3. Association between SFQ and testosterone in male patients with FEP. Linear trend 
line and 95%confidence interval of simple linear regression is plotted in the data.  
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